Render Biotech reached a strategic cooperation with QuidelOrtho
1. Strong cooperation,a new chapter begins
Render biotech, aleading Chinese thrombelastography company, and QuidelOrtho, a pioneer in theglobal clinical laboratory and blood transfusion industry, have reached astrategic cooperation on the distribution channel operation ofthromboelastography products in China, giving full play to Render's productadvantages and QuidelOrtho's brand and business channel advantages , to jointlyserve the vast number of Chinese customers, create a more complete closed loopof pre-blood transfusion diagnosis, and at the same time accelerate the depthof serving customers in the POCT scene. It is reported that the two partieshave cooperated for half a year and have been operating in a low-key manner. Itwas not until a recent online seminar on "Automatic ThromboelastographyTechnology Application" that this cooperation surfaced, which also markedthe official launch of the cooperation between the two parties.
2. Blessings fromexperts and celebrities hope innovate products to set sail
Last Wednesday, the Seminaron the “Application of FullyAutomatic Thromboelastography Technology" was held online with the themeof knowledge transfer and cohesion of new voices. This conference is the firstacademic conference held after QuidelOrtho and Render have reached a strategiccooperation on related businesses. It is intended to further popularize theapplication value and significance of TEG in clinical practice online, and alsoto send blessings to the cooperation between the two parties.
Thromboelastography isa blood viscoelasticity test method widely recognized by the internationalacademic community. This method is famous for its comprehensiveness,directness, sensitivity and high clinical compliance. It has entered theclinical guidelines of nearly 30 countries. Recently, With the gradualpopularization and deepening of domestic clinical applications in 2009, it hasalso been highly recognized by inspection, blood transfusion and even clinicaldepartments.
For example, the useof TEG for coagulation testing and guiding component transfusion has importantclinical implications. The "Guidelines for Pediatric Blood Transfusion(2022 Edition)" clearly pointed out that before operation, if there isstill a lot of bleeding after being antagonized with protamine, TEG should beused to evaluate the hemostatic status to guide treatment; When the child hascoagulation factor deficiency, FFP infusion can be performed according to thetest results. Professor Li Zhiqiang, director of the Blood TransfusionDepartment of Shanghai Sixth People's Hospital, said: "TEG can judge thewhole process of blood coagulation in a short period of time. Using TEG fordetection can guide component blood transfusion and save 20%-50% of bloodproducts." Department of Blood Transfusion, Beijing Hospital ProfessorGong Jiwu, the director, said: "After the promulgation of the"Measures for the Administration of Clinical Blood Use in MedicalInstitutions", the pre-clinical blood evaluation system has beenimplemented. Automatic thromboelastography can be specially used for clinicalprecise blood transfusion guidance, providing patients with more scientificdiagnosis "Professor Wang Deqing, director of the Transfusion MedicineDepartment of the First Medical Center of the Chinese People's Liberation ArmyGeneral Hospital, said: "TEG can be very helpful in clinical evaluation ofblood coagulation function, predicting the risk of thrombus and bleeding, andguiding the application of anticoagulants." Shanghai Professor WangXuefeng, director of the laboratory and blood transfusion department of RuijinHospital, also believes that: "TEG monitors the changes in the coagulationprocess from the whole dynamic process of platelet aggregation, coagulation andfibrinolysis, and is helpful for clinical diagnosis of coagulation dysfunctionand the cause of bleeding."
With the deepening ofresearch, the application potential of TEG in obstetrics, gynecology andcardiology has also been continuously explored. The "Medical and ChildHealth Care Institutions Medical Equipment Standards (2022)" issued inApril 2022 clearly stated for the first time that TEG should be used as acommonly used maternity health care equipment for maternal and child caresystems. Professor Sun Yu, Department of Obstetrics and Gynecology, Peking UniversityFirst Hospital, said: "Pregnant women are a high-risk group forthrombosis. TEG can monitor abnormal blood coagulation, especially for theevaluation of postpartum hemorrhage, and can be used as an important evaluationtool." Director of Cardiology Department of Beijing Hospital ProfessorYang Jiefu said: "The mechanisms that cause cardiovascular diseases arecomplex, but many of them are related to thromboembolism. TEG can detectabnormalities of thromboembolism at an early stage and help clinical departmentsunderstand the effect of treatment."
3. Render starts theera of fully automatic thromboelastography, leading the development of theindustry
Thromboelastography isa method to analyze the whole picture of human blood coagulation function, andit is a necessary means for blood coagulation function detection. However, evenif the existing detection schemes are international brands, there are stillproblems such as low degree of automation, complicated operation, and too manyhuman interference factors. Clinical application pain points obvious. Render'sfirst fully automatic thromboelastography series has taken the leading positionin the world once it was launched. With fully automatic performance and theoriginal patented thromboelastography microfluidic reagent card, it reducesmore than 15 steps compared with traditional equipment, greatly improvingdetection efficiency and accuracy Spend.
At the same time, Renderhas made a full series of multi-model product layouts for different scenariosin the hospital, not only for laboratories such as laboratory and bloodtransfusion departments, but also for clinical departments such as cardiology,obstetrics and gynecology, ICU, and operating rooms. The throughput modelIHTEG12 is designed for hospitals with large-scale sample testing. Samples comein and the results come out. It can be connected to the assembly line withoutmanual on-duty, avoiding biological pollution, and pushing the degree ofautomation to the extreme; ② POCT automatic model ITEG2/ 4/6, adoptsmicrofluidics professional combined with classic suspension wire detectiontechnology, the original tube is put on the machine, one-click direct access,easily relieves the troubles of clinical departments; ③The semi-automaticmodel IMTEG2 is suitable for primary hospitals with less detection volume andis more accurate , more convenient and safer.
About Render
Shenzhen Renderbiotech Co., Ltd. was established in 2016. As a global leader inthromboelastography, it focuses on the research and development, production,marketing and service of innovative products in the field of blood transfusion.It is a "national high-tech enterprise" and "Shenzhen High-techenterprise", the products are exported to more than 60 countries andregions around the world. In 2021, Sequoia Capital China Fund and QimingVenture Partners will jointly empower and complete the A round of financing.The serialized automatic thromboelastograph is leading the market. The productdesign and quality have been praised by experts and customers, and it hasquickly entered many well-known top three medical institutions.
Render focuses onvalue creation, continues to increase innovation and research and development,and is committed to becoming a platform enterprise in the direction of bloodtransfusion diagnosis and treatment in China.
About Quidel Ortho
QuidelOrtho wasestablished by the merger of Quidel, a pioneer in point-of-care diagnostics,and Ortho, a global pioneer in the clinical laboratory and blood transfusionindustry. The company is customer-centric and uses innovation to open up newroutes. QuidelOrtho aims to change the future of the diagnostic industry througha more comprehensive product portfolio and excellence in services.
QuidelOrtho iscurrently one of the largest suppliers of in vitro diagnostics in the world. Ithas been deeply involved in the diagnostic industry for more than 80 years, andits business scope exceeds 130 countries. Focusing on the fields of moleculardiagnosis, clinical laboratory, transfusion medicine and point-of-carediagnosis, QuidelOrtho always strives to improve the health of patients aroundthe world.